ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / SER / financials
GANX (41) IBIO (23) HYPD (38) ANVS (35) ⌘ Pro Terminal β†’

Serina Therapeutics Inc. (SER) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.85 -4.64% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.83

Serina Therapeutics Inc. (SER) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $49.3M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SER Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Serina Therapeutics Inc. (NYSE: SER) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.85 (-4.64% 1D, market cap $49.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SER ranks #768 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SER compare to GANX and IBIO in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SER carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, GANX (Gain Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M) and IBIO (iBio Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $49.4M). Among the 5-stock peer group, SER leads on earnings multiple (N/A) while SER leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SER?
β–Ό

Per SER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001708599), Serina Therapeutics Inc. generated $130.0K in revenue (+132.1% YoY), -$19.2M in net income, and -$18.0M in free cash flow against $7.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.83 (-1.03%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (31/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510031
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (8)Whales (5)SEC (8)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.9% Base Target
$5 Bull$2 Base$1 Bear
πŸ“¬ FREE SER RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SER)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
πŸ” WHY SER SCORES 31/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+8/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
23
Grade E$1.82-8.8% Next Q
Q2 (-2Q)
26
Grade E$1.66+0.6% Next Q
Q3 (-1Q)
28
Grade E$1.67+10.8% Next Q
Current
31
Grade E$1.85-9.4% Hist 90D Ξ±
Trajectory: E (23) β†’ E (31)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a SER Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While SER currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.12) and Max Pain ($1.94) forces dealer call-delta covering toward $5.24.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SERβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSER Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How SER Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$1.0MGross Profit $520.0K (52%)Cost of Sales $480.0KOp Profit $0 (0%)OpEx (R&D/SG&A) $520.0KNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $3.2M
FY24
Rev $56.0K
FY25
Rev $130.0K
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$130.0K52%-80%-$19.2M-$18.0M-45%
FY 2024$56.0K52%-80%-$11.1M-$17.2M-45%
FY 2023$3.2M52%-80%$5.3M-$2.5M-35%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SER)

  • βœ“Walkthrough of SER's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
SER // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.63%β–Ό DESCENDING CHANNEL
2026-11-03O $1.89H $1.94L $1.85C $1.85VOL 155.1K
RES: $2.54SUP: $1.26SMA50: $2.12SMA200: $2.08
$3.72$3.06$2.40$1.74$1.07RES $2.54SUP $1.26$1.852026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SER Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ SER Butterfly Map β†’ + Track SER β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +132.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SER today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SER. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SER today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SER)

Health Care Rank #768 of 1015 βš”οΈ GANX vs SER Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (SER vs. GANX, IBIO, HYPD, ANVS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Serina Therapeutics Inc. (SER) ranks #768 by composite RQD confidence (31/100, grade E) and #747 by equity capitalization ($49.3M). Within this direct 5-issuer industry benchmark cohort, SER leads on earnings valuation at N/A trailing P/E, while SER leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. GANX currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with SER at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SER ACTIVE
Serina Therapeutics Inc.
E 31/100 β€” β€” -35.0% -4.64% $49.3M Benchmark Subject
GANX
Gain Therapeutics Inc.
D- 41/100 β€” β€” -35.0% 0.00% $49.3M /ganx-vs-ser β†’
IBIO
iBio Inc.
E 23/100 β€” β€” -35.0% +4.06% $49.4M /ibio-vs-ser β†’
HYPD
Hyperion DeFi Inc.
D- 38/100 β€” 62.7% -35.0% -7.76% $49.7M /hypd-vs-ser β†’
ANVS
Annovis Bio Inc.
D- 35/100 β€” β€” -35.0% -4.42% $48.2M /anvs-vs-ser β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001708599 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Serina Therapeutics Inc. (SER) reported GAAP revenue of $130.0K (+132.1% vs. FY2024 revenue of $56.0K , and -95.9% cumulative change since FY2023) , GAAP net income of -$19.2M, operating cash flow of -$18.0M, and free cash flow of -$18.0M (-5.0% YoY). On the balance sheet, SER closed FY2025 with $7.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $130.0K -$19.2M -$18.0M -$18.0M $7.0M β€”
FY2024 (FY) 2024-12-31 $56.0K -$11.1M -$17.1M -$17.2M $6.7M β€”
FY2023 (FY) 2023-12-31 $3.2M $5.3M -$2.5M -$2.5M β€” β€”

3. SER Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Serina Therapeutics Inc. (NYSE: SER) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.85 (-4.64% 1D, market cap $49.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SER ranks #768 in composite RQD confidence.

How does SER compare to GANX and IBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SER carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, GANX (Gain Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M) and IBIO (iBio Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $49.4M). Among the 5-stock peer group, SER leads on earnings multiple (N/A) while SER leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SER?

Per SER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001708599), Serina Therapeutics Inc. generated $130.0K in revenue (+132.1% YoY), -$19.2M in net income, and -$18.0M in free cash flow against $7.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SER trading relative to its 50-day, 200-day, and 52-week technical levels?

SER last traded at $1.85 (-4.64% on volume of 38,997 shares), positioning the stock -12.74% below its 50-day simple moving average ($2.12) and -11.06% below its 200-day simple moving average ($2.08). Across its 52-week range of $1.22 to $4.99, SER sits at the 16.7% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.62 to $2.08).

Direct Sub-Reports: SER RQD Cockpit SER 12M Forecast SER Earnings & Move SER Dividends & DRIP SER Insiders & 13F SER Whale Options SER Profit Sankey SER News & Why
ROARABLE RATING BRIEF β€’ RQD 31/100 (E) βœ“ SEC XBRL & RQD VERIFIED

SER β€” Serina Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Serina Therapeutics Inc. (SER) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.85 (-4.64% 1D, market capitalization $49.3M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Serina Therapeutics Inc. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Serina Therapeutics Inc. (SER) reported $130.0K in annual revenue (up from $56.0K in FY2024, +132.1% YoY) and -$19.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.2M revenue, $5.3M net income) through FY2025, SER scaled operating cash flow to -$18.0M and free cash flow to -$18.0M, backed by $7.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $1.22 – $4.99 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), SER carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can SER sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $130.0K and free cash flow of -$18.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SER's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SER Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Serina Therapeutics Inc. (SER) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to SER Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SER Bull vs. Bear Conversation Board β€” What's Your Call at $1.85?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SER 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SER:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER β€’ Growth & Tech Investor πŸ‚ BULLISH 🎯 Target: $2.50 (+28.9%)
πŸ“Œ Pinned Debate

The stock is priced at $1.89 with a 52-week range of $1.22 to $5, and the rating shows a 15.24% daily gain.

The street is overcomplicating Serina Therapeutics Inc. (SER). The stock is priced at $1.89 with a 52-week range of $1.22 to $5, and the rating shows a 15.24% daily gain.. With an RQD score of 31/100 (E) and Forensic Balance Sheet at 8/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $2.10.

RetailWhale_TX πŸ‚ BULL

@CreditSpread_Watch Shorting a 5/20 institutional whale-flow stock at $1.94 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER β€’ Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.63 (-16.0%)
Spot @ $1.94

Reported operating losses widened to -$24.0M on $0.1M of revenue, with ROIC at -35% and FCF yield at 0%.

I respect the product at Serina Therapeutics Inc., but the stock at $1.94 is a different story. Reported operating losses widened to -$24.0M on $0.1M of revenue, with ROIC at -35% and FCF yield at 0%.. FCF yield is 0.0% and RQD sits at 31/100 (E) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE